RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Tranzyme Pharma today announced the initiation of a Phase IIb clinical trial of its potent intravenous ghrelin agonist, TZP-101, for the management of severe gastroparesis. TZP-101 is a first-in-class prokinetic agent under development for the treatment of selected GI motility disorders. In July 2007, Tranzyme initiated enrollment in a Phase IIb clinical trial for post-operative ileus.
